Navigation Links
Apexigen Announces the Filing of an IND by its Partner, 3SBio
Date:8/15/2012

BURLINGAME, Calif., Aug. 15, 2012 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China. Upon approval of the IND, APX001/SSS07 will be studied in clinical trials for the treatment of autoimmune and inflammatory diseases. APX001/SSS07 was discovered through the use of Apexigen's proprietary monoclonal antibody technologies and has been developed by 3SBio in China under a license from Apexigen. APX001/SSS07 is the second antibody discovered through the use of Apexigen's technologies for which an IND has been filed with the SFDA.

"We congratulate our colleagues at 3SBio on this IND filing," said Dr. Xiaodong Yang, President and CEO of Apexigen. "It represents the hard work of many individuals working collaboratively as a team to achieve the common goal. We look forward to continuing success in our collaboration."

About Apexigen, Inc.

Apexigen, Inc. is an emerging biopharmaceutical company focused on improving patient care by translating the unique attributes of its proprietary antibody technologies into superior therapeutics for the treatment of cancer and other difficult-to-treat diseases.  Apexigen has a robust antibody platform technology and a pipeline of seven humanized antibody product candidates.  Apexigen's proprietary antibody technologies produce a broad diversity of antibodies with high specificity and high affinity against unique epitopes.  It can successfully generate antibodies against challenging antigens where competing technologies fail.  This technology allows Apexigen to identify antibodies with unique functional characteristics for optimal therapeutic benefit.

Developing its product pipeline through collaborations is an important aspect of Apexigen's business model.  Several antibodies derived from its technology have been licensed to companies in China who are developing them for commercialization there.  In addition, Apexigen has also licensed the use of its antibody technologies to multinational companies for use in the development of therapeutics worldwide.  Additional information is available at www.apexigen.com.Contacts:

ApexigenMark NevinsVice President, Business Development+1 650 931-6236 ext. 502 


'/>"/>
SOURCE Apexigen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Jan. 20, 2017  Ethicon Endo-Surgery, Inc. ... Medical Products, Inc., a privately held medical ... electrosurgical tools used in operating rooms worldwide. ... Ethicon,s* advanced energy devices with Megadyne,s innovative ... step forward in Ethicon,s goal to deliver ...
(Date:1/20/2017)... Entscheidung fällt als ... Die internationale humanitäre Stadt soll um knapp 2800 m² ... Seine Hoheit Scheich Muhammad bin Raschid ... von Dubai , hat den Auftrag ... Humanitarian City IHC) zu verdreifachen, um den Betrieb zur ...
(Date:1/19/2017)... 2017 The Global Therapy Partnering Terms and ... partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ... The report provides understanding and access to the ... leading healthcare companies. The report provides an analysis ...
Breaking Medicine Technology:
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 , ... ... level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show ... respected bodybuilder and nutritional scientist who was determined to create a line of products ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K ... 4K Mystique lens flare and light leak transitions have a very high-dynamic range for ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
Breaking Medicine News(10 mins):